ライフサイエンスコーパス: disease management

1 lt challenges in medicine and a key facet of disease management.

2 shed case series provide limited guidance on disease management.

3 ive airway diseases and provide guidance for disease management.

4 itate targeting of GAS virulence factors for disease management.

5 recognition and evaluation of the effects of disease management.

6 articles hold the potential to revolutionize disease management.

7 y yield a useful therapeutic agent for heart disease management.

8 kers that can potentially be used to improve disease management.

9 targeted improved primary care and comorbid disease management.

10 resistance may be of grave consequences for disease management.

11 ations and may facilitate decision-making in disease management.

12 ures and suggest novel strategies to improve disease management.

13 kemia (CLL) and have direct implications for disease management.

14 h needed for more personalized treatment and disease management.

15 cal trial results, and current guidelines on disease management.

16 e use of biologics and less costly long-term disease management.

17 rculating tumor cells in cancer research and disease management.

18 y amyloid self-assembly events for potential disease management.

19 improving care transitions, monitoring, and disease management.

20 erium responsible for an outbreak can aid in disease management.

21 de valuable biochemical insights and improve disease management.

22 of familial Mediterranean fever and Behcet's disease management.

23 , is relevant to sustainable development and disease management.

24 myeloid leukemia (AML) remain a challenge in disease management.

25 eatic tumorigenesis, cancer progression, and disease management.

26 eractivity that are useful for diagnosis and disease management.

27 rial and viral infections as well as chronic disease management.

28 s technology used for patient monitoring and disease management.

29 itically ill patients, and effective chronic disease management.

30 ion and trust in the nurse's role in chronic disease management.

31 t may guide the development of new drugs for disease management.

32 to improve its use are essential for optimal disease management.

33 e to therapy, which are important aspects of disease management.

34 a significant challenge for diagnostics and disease management.

35 ents and is a cost-effective strategy in CMV disease management.

36 D, targeted specific therapies could improve disease management.

37 d skin and provide potential new targets for disease management.

38 populations with diagnostic markers will aid disease management.

39 PRT should feature in disease management.

40 amage responses is providing new avenues for disease management.

41 e; their early detection could be a tool for disease management.

42 arely if ever curable and hence need chronic-disease management.

43 f chronic human immunodeficiency virus (HIV) disease management.

44 control remain the mainstays of C. difficile disease management.

45 ied components traditionally associated with disease management.

46 fection court poses important challenges for disease management.

47 form of postacute care, that are included in disease management.

48 ionuclides have not yet found their place in disease management.

49 e used to determine measures of intensity of disease management.

50 m components, with respect to the target for disease management.

51 ctive, well-recognized approaches to chronic disease management.

52 e to these agents is an emerging problem for disease management.

53 or both partners and possible improvement in disease management.

54 ences in etiology that have implications for disease management.

55 blished guidelines for diagnosis and initial disease management.

56 cterial infections is needed to improve lung disease management.

57 ogical processes is imperative for effective disease management.

58 towards personalized medicine and infectious disease management.

59 discuss the significance of new findings for disease management.

60 suppression and serve as biomarkers for CHB disease management.

61 rd may contribute to patient harm and impair disease management.

62 specialist care are paramount in optimizing disease management.

63 ell model, with substantial implications for disease management.

64 pathways as novel therapeutic approaches for disease management.

65 rapy, which have negative effects on primary disease management.

66 to resources and interventions essential for disease management.

67 mpact of pathogen diversity is important for disease management.

68 tial heterogeneity needs to be considered in disease management.

69 biodiversity, and has applied potential for disease management.

70 behavioral subgroups may also be relevant to disease management.

71 seful for resource poor countries for better disease management.

72 ability to transmit parasites would improve disease management.

73 glaucoma surgery (Trabectome) in 2 eyes for disease management.

74 d ecological questions with implications for disease management.

75 arly-stage Alzheimer's disease diagnosis and disease management.

76 es may allow pathogenetic studies to improve disease management.

77 atments of CLL, and, possibly, for optimized disease management.

78 rdiovascular-related lifestyle behaviors and disease management.

79 n essential component of integrated pest and diseases management.

80 ality for preventive care, 71.1% for chronic disease management, 65.5% for maternity care, and 80.8%

81 balancing available biologic, environmental, disease management, access to care, and socioeconomic an

82 Biologic, environmental, disease management, access, and socioeconomic hardship v

83 arly every measured biologic, environmental, disease management, access, and socioeconomic hardship v

84 Contemporary models of chronic disease management across a variety of countries point t

85 rvice-based interventions for cardiovascular disease management also have shown benefits with respect

86 ontributions because biocontrol agents offer disease management alternatives with different mechanism

87 trends in clinical presentation and primary disease management among patients with low-risk prostate

88 ed the use of mobile technologies to improve disease management and 26 trials investigated their use

89 tion differentiation is a critical aspect of disease management and an active research area.

90 e clinical implications for early diagnosis, disease management and care planning and theoretical imp

91 ression of Parkinson's disease could improve disease management and clinical trial design.

92 Such information is important for future disease management and cost savings.

93 hese results carry implications for wildlife disease management and highlight areas for future work,

94 xamples where these principles have enhanced disease management and illustrate how they can be furthe

95 Goals of care are moving toward chronic disease management and improved long-term health.

96 of influenza is critical for improvements in disease management and is especially important for early

97 iting Group began with a conceptual model of disease management and its components and subsequently v

98 isms involved with schizophrenia may improve disease management and may identify new drug targets.

99 e include systematic implementation of liver disease management and new treatment in HIV-infected pop

100 messaging into clinical practice can improve disease management and patient education.

101 eting IDTCs would be crucial for sustainable disease management and prevention of acquired drug resis

102 ing of the role that dietary fat can play in disease management and prevention.

103 We discuss our results in light of virus disease management and the evolutionary advantage of hap

104 urrent pivotal transitions in cardiovascular disease management and their potential influence on the

105 aster on-site diagnosis would infer improved disease management and treatment decisions.

106 fully elucidated, putting limits to current disease management and treatment.

107 ify true disease stage, spuriously informing disease management and ultimately increasing the risk of

108 ol and that biocontrol research might inform disease management and vice versa.

109 ease, (3) defining disease modification, (4) disease management, and (5) implementation research.

110 reviews of 13 RCTs plus 2 additional RCTs of disease management, and 8 RCTs of oxygen.

111 ultidisciplinary approach to thoracic aortic disease management, and a standardized protocol for ATAA

112 The addition of biologic, environmental, disease management, and access variables resulted in 80%

113 well-being, being better informed, improved disease management, and feeling confident in the relatio

114 hortens their "diagnostic odyssey," improves disease management, and fosters genetic counseling with

115 follow-up clinic, outpatient rehabilitation, disease management, and ICU diaries.

116 tightly managed system of care coordination, disease management, and preventive services provided by

117 inhaled therapies, pulmonary rehabilitation, disease management, and supplemental oxygen in adults wi

118 wards better patient compliance and improved disease management, and thereby enhanced patient quality

119 icant limitations on adolescents' self-care, disease management, and transition to adult care.

120 idemiology enabled development of integrated disease management approaches that rely heavily on diver

121 opment of novel therapeutic intervention and disease management approaches.

122 Implications of these findings for disease management are discussed.

123 of biomarkers and therapeutics for effective disease management are limited.

124 New approaches to pest and disease management are needed that take into account the

125 cidation of PARP-1 function into advances in disease management are reviewed.

126 A Disease Management Area (DMA) approach, as developed in

127 Most patients saw chronic disease management as a medicalised approach and the nur

128 progression will provide important tools for disease management, as well as for identifying the under

129 is a critical component of acute and chronic disease management, as well as health and wellness acros

130 Their identification not only affects disease management but also may uncover key mechanisms o

131 ibition of BCR-ABL kinase has revolutionized disease management, but fails to eradicate leukaemic ste

132 ditional epidemiology can be used to improve disease management, but it requires good prior knowledge

133 bably an important contributor to suboptimal disease management, but methodological challenges have l

134 indfulness meditation may complement medical disease management by improving psychological distress a

135 lectronic health records (EHRs) with chronic disease management capabilities support small-practice r

136 ure, diabetes, and depression, together with disease management, case management, and care management

137 to the Medicare program in fees paid to the disease-management companies ($400 million), with no dem

138 The evidential basis for disease management decision making is provided by data r

139 ecological and epidemiological data may aid disease management decision-making by providing a framew

140 e dispersal scales to assist in making plant disease management decisions, such as the timely applica

141 ture therapeutic options when making current disease management decisions.

142 of communication identifies a broad range of disease management delivery systems that may include in-

143 ignificant efforts have been made to develop disease management (DM) programs that will improve clini

144 esenting time available to devote to chronic disease management during patient encounters) and diabet

145 nhibition have shown a significant impact on disease management, emphasizing the importance of the ac

146 ing framework has been suggested for chronic disease management especially where multiple treatment o

147 tiveness and harms of pharmacist-led chronic disease management for community-dwelling adults.

148 controlled trials have shown that nurse-led disease management for patients with heart failure can r

149 o achieve specific objectives in ecology and disease management, for example.

150 Intervention patients received intensive disease management from a multidisciplinary team.

151 management group than the moderate-intensity disease management group (odds ratio [OR], 1.43 [95% CI,

152 d higher abstinence among the high-intensity disease management group than the moderate-intensity dis

153 5% CI, 1.00 to 2.03]) and among the combined disease management groups than the pharmacotherapy-alone

154 icipants in the high- and moderate-intensity disease management groups, respectively (OR, 1.33 [CI, 0

155 Two trials of disease management had low risk of bias; in one, antiret

156 in our understanding of pathogen biology and disease management has been the research capacity and co

157 Disease management has shown great promise as a means of

158 Peer support models for chronic disease management have been successfully applied for ot

159 eman disease have begun to have an impact on disease management; however, the role of these new agent

160 these patients has important diagnostic and disease management implications.

161 ns is essential to strategic and sustainable disease management in agricultural systems.

162 We looked at growth, anthropometry and disease management in children with dual diagnosis (T1DM

163 acerbations will strike and may thus improve disease management in critical care medicine.

164 e dermatology profession needs to understand disease management in dollar terms to advocate on behalf

165 ght critical issues for immunotherapy and HD disease management in general.

166 rom transfusions that represent the basis of disease management in most patients with severe thalassa

167 of histological stage is an integral part of disease management in patients infected with the hepatit

168 ing research to improve stress tolerance and disease management in production systems.

169 t practical applications in animal and human disease management in the face of highly prevalent paras

170 overall viral fitness, with implications for disease management in the future.

171 ients with HF for identifying candidates for disease management in whom increased care may reduce hos

172 nd monitoring CKD for the purpose of chronic disease management (including testing and monitoring pat

173 phy which may have clinical implications for disease management, including prosthetic restoration str

174 n recipient describes the primary targets of disease management intervention and includes patients an

175 (7) Environment defines the context in which disease management interventions are typically delivered

176 thcare providers involved in the delivery of disease management interventions, including nurses, case

177 Chronic disease management is an increasingly important aspect o

178 s of treatment suggest that higher-intensity disease management is associated with increased abstinen

179 role of pulmonary rehabilitation in chronic disease management is highlighted.

180 n Americans (eg, heart failure medications), disease management is less effective among African Ameri

181 The relationship between epidemiology and disease management is long-standing but sometimes tenuou

182 Disease management is multifaceted and multidisciplinary

183 y common thread linking surgical and medical disease management is the abdominal compartment syndrome

184 e in patients willing to contribute to their disease management, limited data exist on the clinical a

185 ole of sentinel-node biopsy and tamoxifen in disease management; locoregional recurrence; and special

186 tion is advantageous in the absence of other disease management methods, especially under conditions

187 A chronic disease management model is effective for treating tobac

188 latform to examine OSA outcomes in a chronic disease management model.

189 and Medicaid Services to test the commercial disease-management model in the Medicare fee-for-service

190 processes and outcomes of effective chronic disease management models and the nursing contributions

191 ngland and Wales ensuring a range of chronic disease management models.

192 ommunity-based support (n = 20), and chronic disease management (n = 3).

193 up to 2 counseling calls (moderate-intensity disease management) (n = 249), or pharmacotherapy supple

194 ith up to 6 counseling calls (high-intensity disease management) (n = 251).

195 essive array of therapies aimed at improving disease management, no means for a practical "cure" exis

196 Neither disease management nor ambulatory oxygen improved measur

197 d have practical applications for infectious disease management of endangered wildlife species.

198 stribution of primary and hepatic metastatic disease, management of chemotherapy, surgery, the sequen

199 der adults for HIV, diagnosis of concomitant diseases, management of multiple comorbid medical illnes

200 t reported 25 outcomes regarding appropriate disease management, of which 11 showed statistically sig

201 host resistance is considered a sustainable disease management option but may often be incomplete or

202 sed oncologic risk when deciding among their disease management options.

203 l examination of the funnel plots for either disease management or health behaviours.

204 or or manage pathogen movement for proactive disease management or quarantine measures.

205 genetics, cultural or social differences in disease management, or low power and statistical chance.

206 rom 2014 to 2034, incorporating cancer risk, disease management, outcome, and cost data.

207 With respect to disease management, partial compliance can undermine att

208 s to aid patient selection, establishment of disease management pathways and collaboration with speci

209 gistered nurses play a large role in chronic disease management, patient education, medication manage

210 Registry-to-Evaluate-Early-And-Long-term PAH disease management)-pediatric criteria, and 32 (15%) acc

211 inic might allow expansion of PET's roles in disease management, perhaps to earlier stages of disease

212 tronic medical records to develop innovative disease management plans that will track asthma over tim

213 tronic medical records to develop innovative disease management plans that will track asthma over tim

214 seed production and utilization, as well as disease management practices applied to seeds.

215 In some high-income countries use of chronic disease management principles and primary care-based col

216 ts from the single-center Duke Heart Failure Disease Management Program between July and December 200

217 Disease management program led by care managers and prov

218 A dementia guideline-based disease management program led to substantial improvemen

219 Over 12 months, the nurse-led disease management program was a reasonably cost-effecti

220 ive cohort study of patients attending an HF disease management program.

221 es on the effectiveness of insecticides in a disease management program.

222 ative person-centred approach, tailoring the disease management programme to address the patient's il

223 ad and impact of disease and may help inform disease management programmes as well as the conservatio

224 Trials investigating efficacy of disease management programs (DMP) in heart failure repor

225 cess, and outcome measures across a range of disease management programs and should promote uniformit

226 t can be used both to categorize and compare disease management programs and to inform efforts to ide

227 Nevertheless, disease management programs are widely heterogeneous and

228 Although disease management programs are widely implemented, litt

229 Although disease management programs for patients hospitalized wi

230 pitals that used postdischarge heart failure disease management programs had lower relative readmissi

231 Disease management programs that target groups with a ch

232 that incurs 70% of health care expenditures, disease management programs to prevent costly complicati

233 echanism for operationalizing and evaluating disease management programs, and as tools for quality as

234 th care interventions, such as heart failure disease management programs, are under increasing pressu

235 ly validated this model over a wide range of disease management programs.

236 Weight gain is used by disease-management programs as a marker of heart failure

237 The eight commercial disease-management programs did not reduce hospital admi

238 In this large study, commercial disease-management programs using nurse-based call cente

239 ed to inform population health approaches to disease management: proportion of cases followed and pro

240 Telephone-based disease management protocols have shown promise in impro

241 Moderate-intensity and high-intensity disease management recipients had postcounseling progres

242 mes than step-up therapy within an intensive disease management regimen.

243 re patterns can help focus crop breeding and disease management research.

244 Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) as a means to compare observ

245 nd Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) equation, REVEAL risk score,

246 Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess pred

247 Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a longitudinal registry of

248 Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

249 Registry to Evaluate Early and Long-Term PAH Disease Management score, the Pulmonary Hypertension Con

250 acy of available treatments, we propose that disease management should primarily be supportive and ed

251 city mechanisms, which may help inform novel disease management strategies against fusarial pathogens

252 e most recent studies on newer therapeutics, disease management strategies and treatment recommendati

253 p received all standard medical, device, and disease management strategies available.

254 This trend must accelerate to provide the disease management strategies needed to maintain global

255 Integrated disease management strategies often exploit cultivar res

256 Effective disease management strategies to prevent catastrophic cr

257 rch and global implementation of generalized disease management strategies to reduce economic and env

258 Increased use of any of 3 disease management strategies was significantly associat

259 Disease management strategies were associated with bette

260 sampled from population-based listings, and disease management strategies were not randomly allocate

261 cations for and effects on plant disease and disease management strategies, are summarized.

262 We also review disease management strategies, including promising new t

263 , and have been useful to develop successful disease management strategies.

264 rovide more efficient clinical diagnosis and disease management strategies.

265 tudies on the development of effective plant disease management strategies.

266 an be used effectively as part of integrated disease management strategies.

267 and conduct of studies that seek to validate disease management strategies.

268 w avenues to improve therapeutic options and disease management strategies.

269 nce of a thorough, independent evaluation of disease-management strategies before their adoption.

270 Disease-management strategies, from telling the patient

271 , and managed to inform the design of better disease-management strategies.

272 Here, we show that this seemingly successful disease management strategy can fail with devastating co

273 conventional DMARDs as part of an intensive disease management strategy.

274 ncer, active surveillance is the recommended disease management strategy.

275 t application of anti-virulence therapy as a disease-management strategy.

276 nts to functioning in the context of chronic disease management, summarize current transition practic

277 cally influenced production of cucurbits and disease management systems at multiple scales.

278 ce of prediction models as part of operation disease management systems.

279 ties for pathogens to exploit, such that new disease management tactics must be discovered and old on

280 ed qualitative research methods to develop a disease management taxonomy with our conceptual model as

281 is problem, the American Heart Association's Disease Management Taxonomy Writing Group developed a sy

282 This statement presents a taxonomy for disease management that describes critical program attri

283 mized study of eight commercial programs for disease management that used nurse-based call centers.

284 d severity to advancements that will improve disease management throughout the lifespan.

285 nalized screening, surveillance, and chronic disease management to help manage chronic conditions, re

286 and new care models, we can redesign chronic disease management to include fewer in-person visits whe

287 nwide data suggest a need for better thyroid disease management to reduce neonatal morbidity.

288 al contribution of quality of cardiovascular disease management to this increased risk.

289 Current disease management tools, such as the Integrated Managem

290 reported outcomes of pharmacist-led chronic disease management versus a comparator for community-dwe

291 up (OR, 1.12 [CI, 0.78 to 1.61] for combined disease management vs. pharmacotherapy alone).

292 Conclusion: Pharmacist-led chronic disease management was associated with effects similar t

293 ent is part of public health surveillance or disease management were excluded.

294 nts' preferences and expectations of chronic disease management were framed by a strongly biomedical

295 Four clinically important questions in bone disease management were identified, and recommendations,

296 Perceptions of nurse-led chronic disease management were often shaped by what was previou

297 eterogeneous and lack a shared definition of disease management, which limits our ability to compare

298 o improvements in prediction, prevention and disease management, which may ultimately reduce the disp

299 clinical development of targeted agents, and disease management with conventional chemotherapy.

300 nary and epidemiological dynamics and inform disease management, yet very little empirical work has a